Cargando…

Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics

Detalles Bibliográficos
Autor principal:	DeBiasi, Roberta L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362545/ https://www.ncbi.nlm.nih.gov/pubmed/34133878 http://dx.doi.org/10.1056/NEJMe2108276

Ejemplares similares

Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021)

MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2021)

Corrigendum: MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2022)

IVIG plus Glucocorticoids versus IVIG Alone in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Systematic Review and Meta-Analysis
por: Rauniyar, Robin, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome-Coronavirus-2 Effects at the Maternal-Fetal Interface
por: DeBiasi, Roberta L
Publicado: (2022)

Do Not Judge a Book by Its Cover: Critical Need for Longitudinal Neurodevelopmental Assessment of In Utero Zika-Exposed Children
por: Mulkey, Sarah B., et al.
Publicado: (2020)

New Insights into Zika in Infants and Children
por: Mulkey, Sarah B., et al.
Publicado: (2022)

Reply
por: DeBiasi, Roberta L.
Publicado: (2020)

The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
por: Gowin, Ewelina, et al.
Publicado: (2022)

Kawasaki Disease, MIS-C and COVID-19
por: Huang, Ying-Hsien, et al.
Publicado: (2023)

Orthoreoviruses and Orbiviruses
por: DeBiasi, Roberta L., et al.
Publicado: (2015)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Editorial: COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Parums, Dinah V.
Publicado: (2021)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Preface of the Special Issue: “Recent CMV Research”
por: Dufrene, Kayla, et al.
Publicado: (2014)

Passive immunotherapy of sepsis with intravenous immune globulin: not all IVIg preparations are created equal
por: Vassilev, Tchavdar, et al.
Publicado: (2012)

Nucleic acid biomarkers of immune response and cell and tissue damage in children with COVID-19 and MIS-C
por: Loy, Conor J., et al.
Publicado: (2023)

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome
por: Bhattiprolu, Rahi Kiran, et al.
Publicado: (2020)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Immune Modulations by Glucocorticoids: From Molecular Biology to Clinical Research
por: J. M. Schaaf, Marcel, et al.
Publicado: (2022)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

542. SARS CoV-2-Associated Multisystem Inflammatory Syndrome of Children (MIS-C) in the Washington DC Metropolitan Region
por: DeBiasi, Roberta L, et al.
Publicado: (2020)

Use and mis-use of supplementary material in science publications
por: Pop, Mihai, et al.
Publicado: (2015)

The Conundrum of Differentiating MIS-C from Dengue and Other Tropical Infections
por: Singhal, Tanu
Publicado: (2023)

Ensuring continued progress for development of COVID-19 therapeutics in children
por: Noel, Gary J., et al.
Publicado: (2021)

Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids
por: Cattaneo, Paolo, et al.
Publicado: (2021)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
por: Zhang, Wei, et al.
Publicado: (2023)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
por: De Groot, Anne S., et al.
Publicado: (2013)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
por: Zhu, Xiao-Lu, et al.
Publicado: (2022)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Search for clinico-biological and echographic correlations of cardiac involvement in MIS-C
por: Boutalbi, N., et al.
Publicado: (2022)

Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial
por: Ali, Shaukat, et al.
Publicado: (2021)

Multisystem inflammatory syndrome in children (MIS-C) and “Near MIS-C”: A continuum?
por: Khafaja, Sarah, et al.
Publicado: (2023)

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

IVIG Effects on Erythrocyte Sedimentation Rate in Children
por: Salehzadeh, Farhad, et al.
Publicado: (2014)

IVIG regulates the survival of human but not mouse neutrophils
por: Schneider, Christoph, et al.
Publicado: (2017)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_14hduruv8ark71ktgrf9bv4pvc